Mapping Institutional Identities and the Production of Ethics
NCT ID: NCT03983863
Last Updated: 2024-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
61 participants
OBSERVATIONAL
2019-05-30
2021-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Researchers want to learn how members of IRB committees interact with each other. They want to see how this affects the decision-making process. They want to learn how members see their role and the roles of their fellow members. They want to see if these views are actualized during meetings. To do this, researchers will sit in on IRB meetings and interview committee members.
Objective:
To explore the dynamics between IRB members. To explore how these dynamics affect the IRB process of decision making.
Eligibility:
NIH IRB staff or members
Design:
In Phase I, an investigator (AI) will sit in on IRB meetings for 6 months. The AI will take notes on the dynamics of the committees. The AI s will focus will be on the dialogue and the behavior of both the group and each member. The AI will also focus on the factors that form the decision-making process. The AI will audio-record the meetings to help take detailed notes. These recordings will be destroyed after 3 months.
If the AI does not hear from members before the IRB meetings, the AI will assume that the member is agreeing to take part in Phase I.
In Phase II, the AI will contact some members about taking part in a 60-minute interview. The interview will be semi-structured. It will be on site and in person. It will explore how the members see their role and the roles of others on the committee.
Contact information will be collected only for members who take part in Phase II.
Data will be de-identified.
Withdrawing from the study will not affect any member s role on the IRB.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genetic Counselors' Experiences of Moral Value Conflicts With Clients
NCT00360711
Mapping Personality Traits to Genes
NCT00001414
Cultural Congruence in International Genetics Research
NCT00767858
Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants
NCT01369953
Use of Population Descriptors in Human Genetic Research
NCT00767702
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The secondary objective of this research is to explore what each member/staff perceives his/her role and the roles of other committee members to be and whether these perceptions are congruent with how roles are actualized during meetings.
Study Population: Our target population consists of all members/staff of NIH IRBs and IRB panels that fall under the NIH Intramural Federal Wide Assurance (FWA).
Design: The project will involve two phases: direct observation and semi-structured interviews. Phase I (direct-observations) will involve an associate investigator, Hina Walajahi, sitting in on regularly scheduled IRB meetings at the NIH and taking observational notes on committee dialogue, individual and group behavior, and factors that contribute to the decision-making process. Meetings will be audio-recorded in order to validate the observation notes. The observational data will be used to select appropriate committee members/staff and guide questions for the semi-structured interviews.
For Phase II (semi-structured interviews), the same associate investigator will conduct in-person, semi-structured interviews with contacted IRB members/staff regarding role perception respective to other members and the committee as a whole. Interviews will last approximately 60 minutes. They will be audio-recorded and transcribed.
Outcome Measures: A qualitative codebook will be created from observational and interview data, focusing on themes including, but not limited to: member interactions, member participation in discussion, committee deliberation processes and voting behavior.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IRB
Our target study population consists of all members/staff of NIH IRBs and IRB panels that fall under the NIH Intramural Federal Wide Assurance (FWA).
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
All members/staff of NIH IRBs and IRB panels that fall under the NIH Intramural Federal Wide Assurance (FWA).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Human Genome Research Institute (NHGRI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sara C Hull, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
National Human Genome Research Institute (NHGRI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Human Genome Research Institute (NHGRI)
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19-HG-N106
Identifier Type: -
Identifier Source: secondary_id
999919106
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.